Oral News and Research

RSS

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company, announced today the initiation of a Phase Ib clinical trial to study the safety and efficacy of RX-3117 in cancer patients with solid tumors.

9 Jan 2014

C. parvum and cryptosporidiosis: an interview with Dr. Momar Ndao, McGill University

Cryptosporidium parvum is one of the most common enteropathogens to affect humans in the world. The protozoan parasite causes a gut infection referred to as cryptosporidiosis.

8 Jan 2014

OxThera announces initiation of Oxabact clinical study in Primary Hyperoxaluria

OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that it has initiated a clinical study in Primary Hyperoxaluria. This announcement bolsters the Company's position as a leader in developing therapies for hyperoxaluria, a debilitating condition that, if untreated, leads to kidney damage and end-stage renal disease.

8 Jan 2014

Cancer Treatment Centers of America recognized with Clinical Nutrition Team of Distinction Award

Cancer Treatment Centers of America has been recognized by the American Society for Parenteral and Enteral Nutrition with the organization's "Clinical Nutrition Team of Distinction Award". Members of the CTCA professional staff will be honored by A.S.P.E.N at its Clinical Nutrition Week Conference in Savannah, GA this January 2014. This award is presented to multi-discipline clinical teams that exemplify excellence in interdisciplinary clinical nutrition practice in compliance with A.S.P.E.N. standards, guidelines and values.

8 Jan 2014

Southfield dentist wins prestigious Patients' Choice Award for the year 2013

Among the select few Dentists honored with the prestigious Patients' Choice Award this year is Sylvan Stern, DDS.

8 Jan 2014

CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today the Company has received approval from the United States Food and Drug Administration (FDA) to commence patient screening of a Phase 2b study of PRO 140, a monoclonal CCR5 antibody, for the treatment of patients with Human Immunodeficiency Virus Type 1.

8 Jan 2014

Research opens door to new direction of PAH treatment

The development of new, more effective vasodilators to treat pulmonary arterial hypertension has been hampered because of their systemic toxicity and adverse side effects. An international team of investigators seeking to surmount these problems and increase drug efficacy have determined that a vascular homing peptide can selectively target hypertensive pulmonary arteries to boost the pulmonary but not systemic effects of vasodilators. Importantly for potential clinical use, this peptide retains its activity when given sublingually. The results using a rat model of PAH are published in the American Journal of Pathology.

8 Jan 2014

Daiichi Sankyo submits Marketing Authorization Application for edoxaban to EMA

Daiichi Sankyo, Company Limited (hereafter, Daiichi Sankyo) today announced that the Marketing Authorization Application for its investigational, oral, once-daily direct factor Xa-inhibitor edoxaban has been submitted to the European Medicines Agency.

7 Jan 2014

Shield Therapeutics reports positive top-line data from pivotal Phase 3 programme of ST10

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces strongly positive top-line data from the pivotal Phase 3 programme of ST10 for the treatment of iron deficiency anaemia in inflammatory bowel disease.

7 Jan 2014

Aeterna Zentaris announces FDA acceptance for filing of macimorelin acetate NDA for AGHD

Aeterna Zentaris Inc. today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for its ghrelin agonist, macimorelin acetate, in Adult Growth Hormone Deficiency. The acceptance for filing of the NDA indicates the FDA has determined that the application is sufficiently complete to permit a substantive review.

7 Jan 2014

Longer duration breastfeeding may reduce risk of rheumatoid arthritis

In a new study of over 7,000 older Chinese women published online today in the journal Rheumatology, breastfeeding - especially for a longer duration - is shown to be associated with a lower risk of rheumatoid arthritis.

6 Jan 2014

Columbia University's College of Dental Medicine selected for 2014 William J. Gies Award

The ADEAGies Foundation, the philanthropic arm of the American Dental Education Association, has selected Columbia University's College of Dental Medicine for a 2014 William J. Gies Award, for outstanding achievement by an academic dental institution in support of dental education. The award recognizes CDM's Community DentCare program, which provides low- or no-cost dental care to children, adults, and seniors in Northern Manhattan and the Bronx.

5 Jan 2014

Metabolon raises $15 million in Series E financing

Metabolon, Inc., a world leader in metabolomics-based diagnostic tests and research services, announced today that it has raised $15 million in a Series E financing through the issuance of preferred stock.

3 Jan 2014

Apple Valley Medical Clinic Sleep Center moves to 14843 Energy Way in Apple Valley

The Apple Valley Medical Clinic's Sleep Center has moved to 14843 Energy Way in Apple Valley. The center, which opened in 2010 under the medical direction of Scott Benson, M.D., a family medicine physician with the Apple Valley Medical Clinic, offers preventive care, diagnosis and referral for treatment of sleep disorders.

3 Jan 2014

Amgen announces romosozumab Phase 2 trial results in postmenopausal women with low BMD

Amgen and UCB (Euronext Brussels:UCB) today announced results from a Phase 2 trial evaluating romosozumab (AMG 785/CDP7851) in postmenopausal women with low bone mineral density (BMD).

2 Jan 2014

FDA accepts Cubist Pharmaceuticals' tedizolid phosphate NDA with Priority Review

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the Company's New Drug Application for its investigational antibiotic tedizolid phosphate (TR-701) with Priority Review. The FDA has assigned a Prescription Drug User Fee Act action date of June 20, 2014. Cubist is seeking FDA approval of tedizolid for the treatment of acute bacterial skin and skin structure infections.

30 Dec 2013

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist.

30 Dec 2013

Keeping teeth and gums healthy through interactive games

Learning about oral health can be informative and fun at the same time. The Pennsylvania Dental Association's (PDA) website features a section specifically designed for kids, and we encourage you to check it out. The Kids' Corner, www.padental.org/kidscorner, is an excellent resource for children of all ages and features the lovable Topher Tooth. It includes interactive games and activities, information on brushing and flossing, answers to frequently asked questions, nutritional information and more.

28 Dec 2013

Perinatal probiotic supplements do not prevent childhood asthma

There is insufficient evidence to support the use of probiotic supplements during pregnancy or infancy to prevent the development of asthma in infants, Canadian researchers report.

27 Dec 2013

Oral ingestion of inosine compound raises urate levels, shows Parkinson's study

New findings published in JAMA Neurology from research into a potentially protective therapy for Parkinson's disease (PD) show that with medical supervision, urate levels may safely be raised while mitigating risk of complications such as gout.

27 Dec 2013

Oral News and Research

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

C. parvum and cryptosporidiosis: an interview with Dr. Momar Ndao, McGill University

OxThera announces initiation of Oxabact clinical study in Primary Hyperoxaluria

Cancer Treatment Centers of America recognized with Clinical Nutrition Team of Distinction Award

Southfield dentist wins prestigious Patients' Choice Award for the year 2013

CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

Research opens door to new direction of PAH treatment

Daiichi Sankyo submits Marketing Authorization Application for edoxaban to EMA

Shield Therapeutics reports positive top-line data from pivotal Phase 3 programme of ST10

Aeterna Zentaris announces FDA acceptance for filing of macimorelin acetate NDA for AGHD

Longer duration breastfeeding may reduce risk of rheumatoid arthritis

Columbia University's College of Dental Medicine selected for 2014 William J. Gies Award

Metabolon raises $15 million in Series E financing

Apple Valley Medical Clinic Sleep Center moves to 14843 Energy Way in Apple Valley

Amgen announces romosozumab Phase 2 trial results in postmenopausal women with low BMD

FDA accepts Cubist Pharmaceuticals' tedizolid phosphate NDA with Priority Review

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Keeping teeth and gums healthy through interactive games

Perinatal probiotic supplements do not prevent childhood asthma

Oral ingestion of inosine compound raises urate levels, shows Parkinson's study

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News